These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 6640005)

  • 1. Low-dose apomorphine and bromocriptine in neuroleptic-induced movement disorders.
    Jeste DV; Cutler NR; Kaufmann CA; Karoum F
    Biol Psychiatry; 1983 Sep; 18(9):1085-91. PubMed ID: 6640005
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.
    Yamada K; Kanba S; Ohnishi K; Ashikari I; Yagi G; Asai M
    Biol Psychiatry; 1997 May; 41(10):1062-4. PubMed ID: 9129786
    [No Abstract]   [Full Text] [Related]  

  • 3. Apomorphine and schizophrenia.
    Johns CA; Levy MI; Davis BM; Mohs RC; Kendler KS; Mathe AA; Trigos G; Horvath TB; Davis KL
    Psychopharmacol Bull; 1984; 20(1):103-7. PubMed ID: 6718635
    [No Abstract]   [Full Text] [Related]  

  • 4. Tardive dyskinesia: clinical and neuroendocrine response to low dose bromocriptine.
    Lenox RH; Weaver LA; Saran BM
    J Clin Psychopharmacol; 1985 Oct; 5(5):286-92. PubMed ID: 4044881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dyskinesia induced by isolated and low-dose bromocriptine].
    Leite I; Lima B
    Acta Med Port; 1992 Jun; 5(6):347. PubMed ID: 1414476
    [No Abstract]   [Full Text] [Related]  

  • 6. [Apomorphine in dyskinesia and psychomotor agitation].
    Stoliarov GV; Markova OF
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(8):97-102. PubMed ID: 7136384
    [No Abstract]   [Full Text] [Related]  

  • 7. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
    Lombertie ER; Durelle G; Fuseau A
    Ann Med Psychol (Paris); 1995 Oct; 153(8):531-4. PubMed ID: 8561400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of intravenous and subcutaneous administration of apomorphine on the clinical symptoms of chronic schizophrenics.
    Syvälahti EK; Säkö E; Scheinin M; Pihlajamäki K; Hietala J
    Br J Psychiatry; 1986 Feb; 148():204-8. PubMed ID: 3516291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bromocriptine in the treatment of patients with parkinsonism and dyskinesias induced by levodopa].
    Haas JA; Lakke JP
    Ned Tijdschr Geneeskd; 1982 Apr; 126(16):701-5. PubMed ID: 7088202
    [No Abstract]   [Full Text] [Related]  

  • 11. Apomorphine and diphasic dyskinesia.
    Durif F; Deffond D; Dordain G; Tournilhac M
    Clin Neuropharmacol; 1994 Feb; 17(1):99-102. PubMed ID: 8149366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apomorphine does not lower the concentration of homovanillic acid in the plasma of normal humans.
    Scheinin M
    Psychopharmacol Bull; 1984; 20(4):660-6. PubMed ID: 6494391
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
    Cortese L; Caligiuri MP; Williams R; Schieldrop P; Manchanda R; Malla A; Harricharan R
    J Clin Psychopharmacol; 2008 Feb; 28(1):69-73. PubMed ID: 18204344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Algorithms for neuroleptic-associated tardive movement disorders.
    Akiyama K
    Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S23-9. PubMed ID: 10560894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic stimulation of subthalamic nucleus elicits oral dyskinesia in rats.
    Parry TJ; Eberle-Wang K; Lucki I; Chesselet MF
    Exp Neurol; 1994 Aug; 128(2):181-90. PubMed ID: 7915675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic and antidyskinetic properties of ergot dopamine agonists.
    Tamminga CA
    Adv Biochem Psychopharmacol; 1980; 23():397-403. PubMed ID: 7395624
    [No Abstract]   [Full Text] [Related]  

  • 19. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series.
    Bona JR
    J Clin Psychopharmacol; 2006 Apr; 26(2):215-6. PubMed ID: 16633158
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.